Dr Per Gerde to deliver opening presentation at DDL25’s ’Pharmaceutical Development Day’

  • 2 december, 2014
  • 15:29

How can we deliver in vitro models that more accurately predict the in vivo behavior of inhaled particles for generic and novel drug developers? What are the key factors preventing the accurate prediction of in vivo bioequivalence when testing in vitro inhaled particles? On Thursday December 11, ISAB founder and Karolinska Institutet Associate Professor Dr Per Gerde opens the second day of the DDL25 (Drug Delivery to the Lungs) Conference.

An annual highlight for scientists working in the aerosol and inhalation field, this year DDL (Drug Delivery to the Lung) celebrates its 25th Anniversary with its DDL25 Conference in Edinburgh, UK 10-12 December.

ISAB founder and inventor of the dry powder aerosol generation R&D platform PreciseInhale, Dr Per Gerde will deliver the opening presentation of DDL25’s ‘Pharmaceutical Development Day’ on Thursday December 11. His presentation, ‘Deposition of Aerosols for Dissolution Experiments: How To Combine One with the Other?’ explores vital factors around deposition and dissolution of in vitro methods when predicting key pharmacokinetic (PK) data in vivo.

Deposition: Complex but crucial
The presentation explores the crucial role that is played by how aerosols are deposited onto test surfaces during dissolution experiments aiming for data ‘good enough’ for predicting bioequivalence in vivo. Dr Gerde’s presentation presents and explores three of the most important parameters to take into account during the deposition process.

“Broadly the talk will explore how we can best simulate in vivo PK data with in vitro systems,” says Dr Gerde. “Drug developers would definitely benefit from being aware of how important the deposition method is in achieving in vitro results that most closely model in vivo results. I will present an overview of the importance of different deposition methods in dissolution experiments. I’ll look at how you can deposit your test aerosols representatively onto your size surface, how much you can pack into the dose, the importance of the thickness and transport capacity of the transport barrier used and how you can perfuse the system with receptor liquid.”

The presentation explores how cross-validating in vitro dissolution data with in vivo findings on dissolution and absorption can contribute crucially. It concludes by exploring the possible effects of static electricity and other factors on the pharmacokinetic performance of drug formulations in in vitro models, and its potential consequences for the bioequivalence of similar formulations.

“I’m very excited to be speaking at DDL,” says Per Gerde. “Whether working on generic or novel inhaled drugs all developers benefit from in vitro models and data that are even better predictors of in vivo findings. This presentation raises some of the most crucial factors for discussion around this. And of course I’ll take questions at the end to take the discussion further. I’m very much looking forward to it.”

If you would like to meet Dr Per Gerde or the ISAB team at DDL25 please contact ISAB below to arrange a time: